Top Markets
#1 Islamic Coin Islamic Coin +151.49%
#2 DOVU DOVU +47.86%
#3 Velvet Velvet +43.20%
#4 Akedo Akedo +42.96%
#5 Black Phoenix Black Phoenix +34.22%
#6 Cross Cross +21.95%
#7 DoubleZero DoubleZero +17.10%
#8 Cap Cap +16.75%
#9 Tutorial Tutorial +15.51%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +9.76%
Coin of the day
Islamic Coin Islamic Coin
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Kedudukan dalam Saham #39467
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Harga Saham
$0.11725176
Disegerakkan terakhir: 2025-07-14
Modal Pasaran
$481.50K
Perubahan (1 hari)
-0.20%
Perubahan (1 tahun)
0.00%
Negara
FR
Perdagangan PHAXIAM Therapeutics S.A. (PHXM)

Kategori

Healthcare
Nisbah P/E bagi PHAXIAM Therapeutics S.A. (PHXM)
Nisbah P/E pada August 2026 TTM: -0.02
Menurut laporan kewangan dan harga saham terkini PHAXIAM Therapeutics S.A., nisbah P/E semasa (TTM) ialah -0.02. Pada akhir 2022, syarikat mempunyai nisbah P/E sebanyak -49.90.
Sejarah nisbah P/E bagi PHAXIAM Therapeutics S.A. dari 2016 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) -0.02 -97.64%
2023 -0.85 -98.30%
2022 -49.90 5,245.05%
2021 -0.93 -47.66%
2020 -1.78 -7.01%
2019 -1.92 -34.61%
2018 -2.93 -53.24%
2017 -6.27 25.89%
2016 -4.98 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -139,643.28%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -155,046.27%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -96,113.43%
BE
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.